Cardiff Oncology (NASDAQ:CRDF) Coverage Initiated by Analysts at Craig Hallum

Research analysts at Craig Hallum assumed coverage on shares of Cardiff Oncology (NASDAQ:CRDF) in a report released on Friday, Briefing.com reports. The firm set a “buy” rating and a $8.00 price target on the stock. Craig Hallum’s price objective indicates a potential upside of 261.99% from the stock’s current price.

Cardiff Oncology Price Performance

Cardiff Oncology stock opened at $2.21 on Friday. The stock has a market capitalization of $102.88 million, a PE ratio of -2.46 and a beta of 1.95. Cardiff Oncology has a 12 month low of $0.94 and a 12 month high of $6.42. The business has a 50 day simple moving average of $2.30 and a 200-day simple moving average of $3.27.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.91%. The firm had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.12 million. During the same quarter in the previous year, the firm posted ($0.25) earnings per share. On average, equities research analysts anticipate that Cardiff Oncology will post -1 EPS for the current fiscal year.

Institutional Trading of Cardiff Oncology

Large investors have recently made changes to their positions in the company. Assenagon Asset Management S.A. boosted its stake in Cardiff Oncology by 380.6% during the second quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock worth $2,699,000 after buying an additional 962,940 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Cardiff Oncology during the second quarter worth $256,000. XTX Topco Ltd acquired a new position in Cardiff Oncology during the second quarter worth $185,000. Renaissance Technologies LLC boosted its stake in Cardiff Oncology by 82.9% during the second quarter. Renaissance Technologies LLC now owns 157,490 shares of the company’s stock worth $350,000 after buying an additional 71,390 shares during the last quarter. Finally, Blair William & Co. IL boosted its stake in Cardiff Oncology by 32.2% during the second quarter. Blair William & Co. IL now owns 227,630 shares of the company’s stock worth $505,000 after buying an additional 55,450 shares during the last quarter. 16.29% of the stock is currently owned by hedge funds and other institutional investors.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.